Figure 3From: Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study Percentage of patients responding per visit, all patients (observed cases per visit). Response was defined as a 50% decrease in MADRS from baseline MADRS score. Visits (Week) 1 (0), 2 (2), 3 (4), 4 (6), 5 (8), 6 (12), 7 (16), 8 (20), 9 (24), 10 (28), 11 (32) and 12 (34)Back to article page